Goswami N, Fredriksen PM, Lundin KEA, et al. - Researchers designed an ENDOCOVID project to explore in the long-term the cardiovascular risk and vascular endothelial function in people living with HIV (PLHIV) therefore demonstrating an important transitional cardiovascular phenotype in COVID-19.

• They will include a sum of 1,026 patients.

• Via clinical and biochemical measurements, cardiovascular research PLHIV with (n = 114 in each of the three recruiting centers) - or without - antiretroviral treatment (ART) (n = 114 in each of the three recruiting centers) with COVID-19 and HIV-negative with COVID-19 (n = 114 in each of the three recruiting centers) will be conducted for cardiovascular risk factors and biomarkers of cardiovascular disease.

• Via brachial artery flow-mediated dilatation, carotid intima-media thickness assessments, and retinal blood vessel analyses, along with vascular endothelial biomarkers and coagulation markers, they will assess vascular and endothelial function.

• The study will evaluate the relationship between HIV-infection in COVID-19 PLHIV with or without ART and its role in the enhancement of cardiovascular risk and endothelial dysfunction at admission, weekly, at discharge and, 4 weeks post-discharge (if possible).